Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07207811 · ClinicalTrials.gov registry record · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
A Phase 3 study of Transthyretin Amyloid Cardiomyopathy (ATTR CM), sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,280
- Enrollment target
- 20
- Study locations
NCT07207811: Recruiting Phase 3 study of Transthyretin Amyloid Cardiomyopathy (ATTR CM), sponsored by Novo Nordisk A/S.
NCT07207811 is a Phase 3 study of Transthyretin Amyloid Cardiomyopathy (ATTR CM) that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 1,280 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07207811, a Phase 3 study of Transthyretin Amyloid Cardiomyopathy (ATTR CM), is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,280 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.
Primary Outcome
Measured as count of events.
Conditions Studied
Interventions
- DRUG NNC6019-0001
- DRUG Placebo (NNC6019-0001)
Study Locations (20)
California
- University of California San Diego (UCSD) - Sulpizio Cardiovascular Center (SCVC) - La Jolla
- Keck School of Medicine USC - Healthcare Consultation Center 2 (HCCII) - Los Angeles
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute - Los Angeles
- UCI Medical Center - Orange
- Profound Research LLC at Southern California Heart Specialists - Pasadena
- University of California, San Francisco Medical Center - San Francisco
- Northbay Cardiology Inc. - Santa Rosa
- Lucile Packard Children's Hospital - Stanford
Illinois
- Northwestern University Clinical and Translational Sciences Institute - Chicago
- The University of Chicago Medicine - Chicago
- Endeavor Health - Glenbrook Hospital - Glenview
Arizona
- Mayo Clinic Hospital - Phoenix
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center - Washington D.C.
Florida
- UF Health Heart and Vascular Hospital - Gainesville
Georgia
- Northeast Georgia Heart Center, Pc (Nghc) - Gainesville
Hawaii
- The Queen's Medical Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,280 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2029-06-29 |
| Phase | Phase 3 |
What NCT07207811 shows while recruiting
NCT07207811 is an interventional study that assigns participants to a tested intervention. Its 1,280 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% higher).
The record links to 1 condition, with Transthyretin Amyloid Cardiomyopathy (ATTR CM) appearing as the primary indexed condition, and to 2 interventions - of which NNC6019-0001 is the first listed.
NCT07207811 names 20 study sites across 11 states, led by California, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT07207811 about?
NCT07207811 is a clinical study titled "CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis". This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a tr...
What is the current status of trial NCT07207811?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,280 participants. The study started on 2025-10-02. Estimated completion is 2029-06-29.
What conditions does trial NCT07207811 study?
This clinical trial studies the following conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM).
What interventions are being tested in trial NCT07207811?
The interventions under investigation include: NNC6019-0001 (DRUG), Placebo (NNC6019-0001) (DRUG).
Who is sponsoring clinical trial NCT07207811?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07207811 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07207811's enrollment target sits among peer trials
1,280 198th of 2000 higher than 1,802 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT07001800 · 1,276 participants · Phase 2
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI